Name: Phenytoin Antibody (Mouse Monoclonal)
Brand: Molecular Depot
SKU: A2010005
Availability: InStock
Rating: 4.7 (6 reviews)

Phenytoin Antibody (Mouse Monoclonal)

Price range: $350.00 through $1,450.00

Catalog #: A2010005 – 0.25 mg

Mouse monoclonal antibody to phenytoin (a drug used to treat seizures, heart arrhythmia, and neuropathic pain). Six clones are available: 1E5, 4D8, 8H9, 2C6, 5H7 and 9F3. Antibodies can be used in ELISA formats as a well as western blot and other immuno-detection methods. Bulk pricing and biotinylation services are available. Live Enquiry about this product via Text/SMS: 1-858-900-3210 (8 am – 8 pm PST).

Clone	Catalog #
1E5	A2010005-1E5
4D8	A2010005-4D8
8H9	A2010005-8H9
2C6	A2010005-2C6
5H7	A2010005-5H7
9F3	A2010005-9F3
6-Clone Set	A2010005-SET

Clone

Clear

SKU: A2010005 Category: Antibodies Tag: MD 1000

Product Description

4.7/5 - (6 votes)

Mouse Phenytoin Antibody (Monoclonal). 6 different clones are available.

Catalog #	A2010005-1E5 A2010005-4D8 A2010005-8H9 A2010005-2C6 A2010005-5H7 A2010005-9F3 A2010005-SET
Size	0.25 mg
Other Names	Mab to Phenytoin, antibody to Phenytoin
Host	Mouse
Concentration	1.0 mg/mL
Purity	>90% (protein A column)
Storage	-20°C. Avoid repeated freeze/thaw cycles.
Supplied as	Liquid solution
Buffer	1X Phosphate Buffer Saline, pH 7.4 + 0.05% sodium azide.
Keywords	Phenytoin, mouse monoclonal antibody

References

Phenytoin: 80 years young, from epilepsy to breast cancer, a remarkable molecule with multiple modes of action. Keppel Hesselink JM, Kopsky DJ. J Neurol. 2017 Aug;264(8):1617-1621.
Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs. DeToledo JC, Ramsay RE. Drug Saf. 2000 Jun;22(6):459-66.
Application of in vivo metabolomics to preclinical/toxicological studies: case study on phenytoin-induced systemic toxicity. Kamp H, Fabian E, Groeters S, Herold M, Krennrich G, Looser R, Mattes W, Mellert W, Prokoudine A, Ruiz-Noppinger P, Strauss V, Walk T, Wiemer J, van Ravenzwaay B. Bioanalysis. 2012 Sep;4(18):2291-301.
Unbound phenytoin plasma concentrations in patients comedicated with sodium valproate–the predictive value of plasma albumin concentration. Johnson GJ, Kilpatrick CJ, Bury RW, Fullinfaw RO, Moulds RF. Br J Clin Pharmacol. 1989 Jun;27(6):843-9.
Phenytoin prodrug 3-phosphoryloxymethyl phenytoin (ACC-9653): pharmacokinetics in patients following intravenous and intramuscular administration. Boucher BA, Bombassaro AM, Rasmussen SN, Watridge CB, Achari R, Turlapaty P. J Pharm Sci. 1989 Nov;78(11):929-32.
Pharmacokinetics of phenytoin following intravenous and intramuscular administration of fosphenytoin and phenytoin sodium in the rabbit. Muchohi SN, Kokwaro GO, Maitho TE, Munenge RW, Watkins WM, Edwards G. Eur J Drug Metab Pharmacokinet. 2002 Apr-Jun;27(2):83-9.
Phenytoin pharmacokinetics following oral administration of phenytoin suspension and fosphenytoin solution to rats. Burstein AH, Cox DS, Mistry B, Eddington ND. Epilepsy Res. 1999 Apr;34(2-3):129-33.
Phenytoin as an effective treatment for polymorphic ventricular tachycardia due to QT prolongation in a patient with multiple drug intolerances. Yager N, Wang K, Keshwani N, Torosoff M. BMJ Case Rep. 2015 Jun 12;2015:bcr2015209521.